Biophytis SA American Depositary Share (0.01 Euro) SEC Filings

BPTS NASDAQ

Welcome to our dedicated page for Biophytis SA American Depositary Share (0.01 Euro) SEC filings (Ticker: BPTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Struggling to trace BIO101’s latest trial data across hundreds of pages? Biophytis SA’s biotechnology filings layer dense clinical results on top of dilution-heavy financing notes—making it hard to spot what really moves the stock.

StockTitan’s AI reads every new document the moment it hits EDGAR, then serves you plain-English answers to the questions you actually ask, from “Biophytis insider trading Form 4 transactions” to “Biophytis quarterly earnings report 10-Q filing”. Our engine extracts R&D spend trends, summarizes risk factors, and flags fresh capital raises—so you no longer comb through footnotes for trial timelines or ADR issuance details. Want real-time alerts? You’ll see “Biophytis Form 4 insider transactions real-time” on your dashboard seconds after insiders file.

Every filing type is covered: the “Biophytis annual report 10-K simplified” shows pipeline probability of success; the “Biophytis proxy statement executive compensation” breaks out option grants tied to clinical milestones; and the “Biophytis 8-K material events explained” highlights sudden trial pauses or licensing deals. Need deeper context? Click into “Biophytis earnings report filing analysis” for AI-generated tables that link Phase 2 data to revenue forecasts, or explore “understanding Biophytis SEC documents with AI” to see how convertible debt may impact future dilution. Whether you’re tracking “Biophytis executive stock transactions Form 4” for insider sentiment or comparing quarter-over-quarter cash burn, our platform turns complex biotech disclosures into actionable intelligence—updated in real time and explained simply.

06/24/2025 12:18 PM

Filing

[6-K] Biophytis SA American Depositary Share (0.01 Euro) Current Report (Foreign Issuer)

Rhea-AI Summary

Biophytis S.A. (ticker: BPTS) filed a Form 6-K on June 24, 2025, to alert investors that, on June 19, 2025, it issued a press release announcing the temporary suspension of trading of its shares. The filing attaches the press release as Exhibit 99.1. No further details—such as the duration, cause, or expected resolution of the suspension—are provided in the submission. The only signatory is Chairman and CEO Stanislas Veillet. Because the document offers no financial statements, earnings data, or transaction details, its sole material disclosure is the trading halt.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Biophytis SA American Depositary Share (0.01 Euro) (BPTS)?

The current stock price of Biophytis SA American Depositary Share (0.01 Euro) (BPTS) is $8.22 as of February 7, 2025.

What is the market cap of Biophytis SA American Depositary Share (0.01 Euro) (BPTS)?

The market cap of Biophytis SA American Depositary Share (0.01 Euro) (BPTS) is approximately 2.4M.

What is the core focus of Biophytis SA?

Biophytis SA is a clinical-stage biotechnology company focused on developing innovative drug candidates to address age-related diseases such as sarcopenia, obesity, and respiratory disorders.

What makes BIO101 (20-hydroxyecdysone) significant?

BIO101 is a lead small molecule candidate with potential applications across multiple indications, including muscular diseases, metabolic disorders, and respiratory conditions, highlighting its versatility and therapeutic potential.

Where is Biophytis SA headquartered?

The company is based in Paris, France, with additional operational support from its facilities in Cambridge, Massachusetts, enabling a blend of European research excellence and North American clinical expertise.

How does Biophytis SA advance its clinical development programs?

The company employs robust clinical development strategies, including multi-phase trials, industrial-scale manufacturing transfers, and strategic partnerships to validate the safety and efficacy of its drug candidates.

What role do strategic partnerships play in Biophytis' business model?

Strategic partnerships, including licensing and co-development agreements, enable Biophytis to expand its market reach and optimize clinical development, thereby reinforcing its competitive position in the biotech industry.

How does Biophytis address the challenges of market and regulatory environments?

Biophytis incorporates comprehensive clinical data, advanced manufacturing practices, and nuanced financing strategies to navigate market challenges and ensure strict compliance with regulatory standards.